The myths on nephrotoxicity

Fungal infections, in particular candidemia, are a growing problem in immunocompetent patients [1]. Despite several guidelines, concern exists on the value of evidence supporting recommendations for the optimal treatment of candidemia in non-neutropenic adult patients [1,2]. In the midst of this controversy a critical reappraisal of the 2009 Infectious Diseases Society of America (IDSA) guidelines is appropriate [1]. Although many relevant aspects of the guidelines are thoroughly discussed, there are three topics that deserve a closer look: the weight and quality of the evidence; the evidence of effi cacy; and the evidence of amphotericin-B (AmB)-induced renal failure.